ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Male Patients With Lower Urinary Tract Syndrome
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2007-10-22
- Lead Sponsor
- Astellas Pharma Inc
- Registration Number
- NCT00239317
A Study to Assess the Safety and Efficacy of a Tacrolimus New Oral Formulation (MR4) in BMT Patients-Extension-
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-09-20
- Lead Sponsor
- Astellas Pharma Inc
- Registration Number
- NCT00189748
A Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in BMT Recipients
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2006-09-20
- Lead Sponsor
- Astellas Pharma Inc
- Registration Number
- NCT00189761
A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2014-08-28
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 691
- Registration Number
- NCT00189813
Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-04-17
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 160
- Registration Number
- NCT00189722
A Study to Evaluate FK778 in Kidney Transplant Patients
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-04-17
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 364
- Registration Number
- NCT00189735
Dose Response of Inhaled Tacrolimus in Patients With Moderate Persistent Asthma
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-04-17
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 370
- Registration Number
- NCT00189787
Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-03-13
- Lead Sponsor
- Astellas Pharma Inc
- Registration Number
- NCT00189774
A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-11-17
- Lead Sponsor
- Astellas Pharma Inc
- Registration Number
- NCT00189800
Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Astellas Pharma Inc
- Registration Number
- NCT00189696
© Copyright 2024. All Rights Reserved by MedPath